COVID Vaccine Response Varies by Blood Cancer Type, Treatment
Patients with AML and high-risk MDS had stronger immune responses after two vaccine doses than patients with ALL. This study was published as a preprint and has not yet been peer reviewed.
First Look
source https://www.medscape.com/viewarticle/972428?src=rss
First Look
source https://www.medscape.com/viewarticle/972428?src=rss
Comments
Post a Comment